<DOC>
	<DOCNO>NCT00573547</DOCNO>
	<brief_summary>The purpose study test whether once-weekly prozac therapy lead reduction depression patient require kidney dialysis .</brief_summary>
	<brief_title>Open Label Trial Fluoxetine Treatment Depression Patients With End Stage Renal Disease</brief_title>
	<detailed_description>Once-weekly Prozac psychiatric medicine , approve FDA use treatment psychiatric disorder . This study test whether once-weekly Prozac lead reduce symptom depression . Patients require dialysis often report symptom depression either due presence major depression , relatively common psychiatric disorder , due depression secondary kidney failure .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Diagnosis chronic renal failure end stage renal disease Ongoing need regular dialysis treatment Diagnosis depression base DSMIV Age tween 1965 year Inability provide inform consent Medically psychiatrically unstable , define require inpatient treatment Pregnancy , nurse refusal use reliable method birth control woman Patients know allergy fluoxetine , previous treatment failure fluoxetine</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>depression</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>end stage renal disease</keyword>
</DOC>